• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用蒸发抗溶剂技术进行纳米结晶以提高替米沙坦的溶解度和生物利用度。

Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan.

机构信息

Department of Pharmaceutics, SVKM'S B.N. College of Pharmacy, Mumbai, India.

出版信息

AAPS PharmSciTech. 2012 Dec;13(4):1331-40. doi: 10.1208/s12249-012-9860-x. Epub 2012 Sep 28.

DOI:10.1208/s12249-012-9860-x
PMID:23054986
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3513472/
Abstract

Telmisartan is an orally active nonpeptide angiotensin II receptor antagonist used in the management of hypertension. It is a Biopharmaceutics Classification System class II drug having aqueous solubility of 9.9 μg/ml. Telmisartan (TEL) nanocrystals were prepared by evaporative antisolvent precipitation technique using different stabilizers as PVPK30, TPGS, Poloxamer 188, and PEG 6000 in combination or singly. The nanosuspensions were characterized in terms of particle size distribution, zeta potential, and polydispersity index. The suspension containing PVPK30 and TPGS (1:1) showed least average particle size of 82.63 nm and polydispersity index of 0.472. The zeta potential of nanosuspensions ranged between 6.54 and 10.8 mV. An increase of 116.45% was evident in the specific surface area of the freeze-dried product. Contact angle of nanoparticles was also lowered to 27° as compared to 50.8° for TEL. Saturation solubility studies in various media revealed a significant increase in comparison to plain drug. An increase of 3.74× in saturation solubility in FaSSIF and 5.02× in FeSSIF was seen. In vitro dissolution profile of nanosuspension coated on pellets revealed release of 85% in water, 95% in 0.1 N HCl, and 75% in phosphate buffer in 30 min. Nanosuspensions were found to be stable in the presence of univalent and bivalent electrolytes. A tenfold increase in bioavailability was evident. Nanoparticles of telmisartan prepared by bottom-up technique proved to be effective in improving the oral bioavailability as a result of enhanced solubility and dissolution rate.

摘要

替米沙坦是一种口服活性的非肽类血管紧张素 II 受体拮抗剂,用于治疗高血压。它是一种生物药剂学分类系统 II 类药物,水溶解度为 9.9μg/ml。替米沙坦(TEL)纳米晶体通过蒸发抗溶剂沉淀技术制备,使用不同的稳定剂如 PVPK30、TPGS、泊洛沙姆 188 和 PEG 6000 组合或单独使用。纳米混悬液的特征在于粒径分布、Zeta 电位和多分散指数。含有 PVPK30 和 TPGS(1:1)的混悬液表现出最小的平均粒径为 82.63nm 和多分散指数为 0.472。纳米混悬液的 Zeta 电位在 6.54 到 10.8mV 之间。冻干产物的比表面积明显增加了 116.45%。纳米颗粒的接触角也从 TEL 的 50.8°降低到 27°。在各种介质中的饱和溶解度研究显示出与原药相比有显著增加。在 FaSSIF 中的饱和溶解度增加了 3.74 倍,在 FeSSIF 中增加了 5.02 倍。包衣在丸剂上的纳米混悬液的体外释放曲线显示,在水中释放 85%,在 0.1N HCl 中释放 95%,在磷酸盐缓冲液中 30 分钟内释放 75%。纳米混悬液在一价和二价电解质存在下是稳定的。生物利用度增加了 10 倍。通过自下而上的技术制备的替米沙坦纳米颗粒由于溶解度和溶解速率的提高,被证明能有效提高口服生物利用度。

相似文献

1
Nanocrystallization by evaporative antisolvent technique for solubility and bioavailability enhancement of telmisartan.采用蒸发抗溶剂技术进行纳米结晶以提高替米沙坦的溶解度和生物利用度。
AAPS PharmSciTech. 2012 Dec;13(4):1331-40. doi: 10.1208/s12249-012-9860-x. Epub 2012 Sep 28.
2
Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.采用Box-Behnken设计研究变量对替米沙坦纳米混悬液粒径的影响。
Drug Res (Stuttg). 2014 Dec;64(12):663-7. doi: 10.1055/s-0034-1368701. Epub 2014 Feb 18.
3
Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.表面稳定化坎地沙坦西酯纳米晶的研制,提高了溶解速率、跨 CaCo-2 的渗透速率和口服生物利用度。
Drug Deliv Transl Res. 2016 Oct;6(5):498-510. doi: 10.1007/s13346-016-0297-8.
4
Solubilization of the poorly water soluble drug, telmisartan, using supercritical anti-solvent (SAS) process.使用超临界抗溶剂(SAS)工艺增溶难溶性药物替米沙坦。
Int J Pharm. 2013 Jan 30;441(1-2):50-5. doi: 10.1016/j.ijpharm.2012.12.020. Epub 2012 Dec 20.
5
Nanosuspension coated multiparticulates for controlled delivery of albendazole.载药纳米混悬剂多颗粒制剂用于阿苯达唑的控释给药。
Drug Dev Ind Pharm. 2021 Mar;47(3):367-376. doi: 10.1080/03639045.2021.1879830. Epub 2021 Mar 15.
6
Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.通过介质研磨技术提高口服生物利用度的头孢地尼纳米混悬液:制剂、表征及体内外评价
Drug Dev Ind Pharm. 2016;42(5):758-68. doi: 10.3109/03639045.2015.1104344. Epub 2015 Nov 7.
7
Amorphous ternary cyclodextrin nanocomposites of telmisartan for oral drug delivery: improved solubility and reduced pharmacokinetic variability.替米沙坦口服给药的无定形三元环糊精纳米复合材料:提高溶解度和降低药代动力学变异性。
Int J Pharm. 2013 Sep 10;453(2):423-32. doi: 10.1016/j.ijpharm.2012.08.034. Epub 2012 Aug 28.
8
Nanosuspensions as delivery system for gambogenic acid: characterization and in vitro/in vivo evaluation.纳米混悬剂作为 Gambogenic 酸的递送系统:特性分析及体外/体内评价。
Drug Deliv. 2016 Oct;23(8):2772-2779. doi: 10.3109/10717544.2015.1077294. Epub 2015 Aug 18.
9
Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution.依非韦伦通过超声辅助IV-抗溶剂纳米结晶法实现的溶出度增强、物理稳定性及溶出情况
AAPS PharmSciTech. 2017 Nov;18(8):3011-3020. doi: 10.1208/s12249-017-0781-6. Epub 2017 May 10.
10
Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.采用沉淀-超声法制备硝苯地平纳米混悬剂以提高其溶解性能和口服生物利用度。
Eur J Pharm Sci. 2010 Jul 11;40(4):325-34. doi: 10.1016/j.ejps.2010.04.006. Epub 2010 Apr 22.

引用本文的文献

1
Nano-formulations in disease therapy: designs, advances, challenges, and future directions.疾病治疗中的纳米制剂:设计、进展、挑战及未来方向。
J Nanobiotechnology. 2025 May 30;23(1):396. doi: 10.1186/s12951-025-03442-7.
2
Effect of Process Parameters on Nano-Microparticle Formation During Supercritical Antisolvent Process Using Mixed Solvent: Application for Enhanced Dissolution and Oral Bioavailability of Telmisartan Through Particle-Size Control Based on Experimental Design.使用混合溶剂的超临界抗溶剂过程中工艺参数对纳米-微粒形成的影响:基于实验设计通过粒度控制提高替米沙坦的溶出度和口服生物利用度的应用
Pharmaceutics. 2024 Nov 24;16(12):1508. doi: 10.3390/pharmaceutics16121508.
3
Eradication of Therapy-Resistant Cancer Stem Cells by Novel Telmisartan Derivatives.新型替米沙坦衍生物对治疗抵抗性癌症干细胞的根除作用
J Med Chem. 2025 Jan 9;68(1):287-306. doi: 10.1021/acs.jmedchem.4c01865. Epub 2024 Dec 18.
4
Microneedles and Their Application in Transdermal Delivery of Antihypertensive Drugs-A Review.微针及其在抗高血压药物经皮给药中的应用——综述
Pharmaceutics. 2023 Jul 27;15(8):2029. doi: 10.3390/pharmaceutics15082029.
5
Development of Olive Oil Containing Phytosomal Nanocomplex for Improving Skin Delivery of Quercetin: Formulation Design Optimization, In Vitro and Ex Vivo Appraisals.用于改善槲皮素皮肤递送的含植物脂质体纳米复合物橄榄油的开发:制剂设计优化、体外和离体评价
Pharmaceutics. 2023 Mar 31;15(4):1124. doi: 10.3390/pharmaceutics15041124.
6
Influence of Poloxamer on the Dissolution and Stability of Hot-Melt Extrusion-Based Amorphous Solid Dispersions Using Design of Experiments.泊洛沙姆对基于热熔挤出的非晶态固体分散体的溶出度和稳定性的影响:实验设计法
AAPS PharmSciTech. 2023 Apr 26;24(5):107. doi: 10.1208/s12249-023-02562-3.
7
A SWOT analysis of nano co-crystals in drug delivery: present outlook and future perspectives.药物递送中纳米共晶体的SWOT分析:当前展望与未来前景
RSC Adv. 2023 Mar 7;13(11):7339-7351. doi: 10.1039/d3ra00161j. eCollection 2023 Mar 1.
8
Hydroxypropyl-β-cyclodextrin Enhances Oral Absorption of Silymarin Nanoparticles Prepared Using PureNano™ Continuous Crystallizer.羟丙基-β-环糊精增强了使用PureNano™连续结晶器制备的水飞蓟素纳米颗粒的口服吸收。
Pharmaceutics. 2022 Feb 10;14(2):394. doi: 10.3390/pharmaceutics14020394.
9
Development and Evaluation of Tannic Acid-Coated Nanosuspension for Enhancing Oral Bioavailability of Curcumin.用于提高姜黄素口服生物利用度的单宁酸包衣纳米混悬液的研制与评价
Pharmaceutics. 2021 Sep 13;13(9):1460. doi: 10.3390/pharmaceutics13091460.
10
Phase transited asymmetric membrane floating nanoparticles: a means for better management of poorly water-soluble drugs.相转变不对称膜浮载纳米粒:改善难溶性药物制剂的手段
Daru. 2021 Dec;29(2):241-253. doi: 10.1007/s40199-020-00382-5. Epub 2021 Aug 20.

本文引用的文献

1
Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension.盐酸瑞伐拉赞纳米混悬剂的制备及体外/体内评价。
Int J Pharm. 2011 Apr 15;408(1-2):157-62. doi: 10.1016/j.ijpharm.2011.01.059. Epub 2011 Feb 2.
2
Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products.药物纳米晶体的自上而下制备:纳米混悬液的稳定化、小型化及转化为固体产品
Int J Pharm. 2008 Nov 19;364(1):64-75. doi: 10.1016/j.ijpharm.2008.07.023. Epub 2008 Jul 31.
3
Micronization of gemfibrozil by reactive precipitation process.通过反应沉淀法对吉非贝齐进行微粉化处理。
Int J Pharm. 2008 Aug 6;360(1-2):58-64. doi: 10.1016/j.ijpharm.2008.04.026. Epub 2008 Apr 22.
4
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.通过晶体工程优化活性药物成分以提高溶解度和溶出速率。
Adv Drug Deliv Rev. 2007 Jul 30;59(7):617-30. doi: 10.1016/j.addr.2007.05.011. Epub 2007 May 29.
5
Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.使用一种筛选方法来确定可优化过饱和药物溶液的程度和稳定性的辅料,并将该系统应用于固体剂型设计。
Int J Pharm. 2007 Sep 5;342(1-2):168-75. doi: 10.1016/j.ijpharm.2007.05.006. Epub 2007 May 13.
6
Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization.通过反溶剂沉淀法制备药物纳米颗粒:混合能与表面活性剂稳定作用
Langmuir. 2006 Oct 10;22(21):8951-9. doi: 10.1021/la061122t.
7
Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs.用于提高难溶性药物溶出度的纳米混悬液的制备与评价
Int J Pharm. 2006 Apr 7;312(1-2):179-86. doi: 10.1016/j.ijpharm.2006.01.008. Epub 2006 Feb 15.
8
Research strategies for safety evaluation of nanomaterials, part V: role of dissolution in biological fate and effects of nanoscale particles.纳米材料安全性评价的研究策略,第五部分:溶解在纳米级颗粒生物学命运和效应中的作用
Toxicol Sci. 2006 Mar;90(1):23-32. doi: 10.1093/toxsci/kfj084. Epub 2006 Jan 4.
9
In vivo pharmacokinetic and tissue distribution studies in mice of alternative formulations for local and systemic delivery of Paclitaxel: gel, film, prodrug, liposomes and micelles.紫杉醇局部和全身给药替代制剂(凝胶、薄膜、前药、脂质体和胶束)在小鼠体内的药代动力学和组织分布研究
Curr Drug Deliv. 2005 Jan;2(1):35-44. doi: 10.2174/1567201052772852.
10
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.通过高压均质法制备的难溶性药物的药物纳米晶体。
Eur J Pharm Biopharm. 2006 Jan;62(1):3-16. doi: 10.1016/j.ejpb.2005.05.009. Epub 2005 Aug 29.